Progress on diagnosis and treatment of multisystem inflammatory syndrome in children

Area of Science:

• Pediatric infectious diseases
• Immunology
• Critical care medicine

Background:

• COVID-19 primarily impacted adults, but SARS-CoV-2 infection has led to increased pediatric cases of Multisystem Inflammatory Syndrome in Children (MIS-C).
• MIS-C pathogenesis involves immune-mediated mechanisms, including cytokine storms and endothelial damage post-SARS-CoV-2 infection.

Purpose of the Study:

• To comprehensively review Multisystem Inflammatory Syndrome in Children (MIS-C).
• To outline diagnostic criteria from major health organizations.
• To summarize current treatment strategies for MIS-C.

Main Methods:

• Literature review of definitions and treatment approaches for MIS-C.
• Synthesis of information from CDC, WHO, and RCPCH guidelines.
• Analysis of current therapeutic interventions.

Main Results:

• MIS-C is defined by persistent fever, intense inflammation, and multi-organ dysfunction.
• Diagnostic criteria vary slightly among CDC, WHO, and RCPCH.
• Treatment focuses on immunotherapy (intravenous immunoglobulin, corticosteroids) and anticoagulation.

Conclusions:

• MIS-C is a significant pediatric complication of SARS-CoV-2 infection requiring prompt recognition.
• Standardized definitions aid in diagnosis and management.
• Immunotherapy and supportive care are key to treating MIS-C effectively.